In MTAP-deficient non-small cell lung cancer, the type I PRMT inhibitor MS023 combined with the PARP inhibitor talazoparib induces greater DNA damage and significantly reduces cell viability [596]. The gene discussed is MTAP; the disease is non-small cell lung carcinoma.